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Abstract
Objective
This study aims to explore the contribution of implicit attitudes and associations towards
conventional disease-modifying antirheumatic drugs (cDMARDs), alongside explicit mea-
sures, on medication-taking behaviour and clinical outcomes in adult patients with rheuma-
toid arthritis (RA).
Methods
In this observational study, implicit attitudes (positive-negative) and health-related associa-
tions (health-sickness) were measured with Single Category Implicit Association Tests,
whereas explicit outcomes were measured with a bipolar evaluative adjective scale and the
Beliefs about Medicines Questionnaire Specific. The primary outcome of this study was
medication-taking behaviour subjectively measured by self-report (i.e. validated Compliance
Questionnaire on Rheumatology) and objectively measured with electronic drug monitors
over a 3 month period. Spearman rank correlations were used to describe correlations
between implicit and explicit outcomes. Nested linear regression models were used to
assess the additional value of implicit measures over explicit measures and patient-, clini-
cal-, and treatment-related characteristics.
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Results
Of the 1659 initially-invited patients, 254 patients with RA agreed to participate in this study.
Implicit attitudes correlated significantly with necessity-concerns differential (NCD) scores
(ρ = 0.13, P = 0.05) and disease activity scores (ρ = -0.17, P = 0.04), whereas implicit
health-related associations correlated significantly with mean scores for explicitly reported
health-related associations (ρ = 0.18, P = 0.004). Significant differences in age, number of
DMARDs, biologic DMARD use, NCD-scores, and self-reported correct dosing were found
between the four attitudinal profiles. Nested linear regression models revealed no additional
value of implicit measures in explaining self-reported medication-taking behaviour and clini-
cal outcomes, over and above all other variables.
Conclusion
Implicit attitudes and associations had no additional value in explaining medication-taking
behaviour and clinical outcomes over and above often used explicitly measured characteris-
tics, attitudes and outcomes in the studied population. Only age and NCD scores contrib-
uted significantly when the dependent variable was correct dosing measured with self-
report.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by synovial inflam-
mation, which can lead to irreversible articular damage, a decrease in physical functioning and
quality of life, and eventually increased healthcare expenditures [1–5]. Conventional disease-
modifying antirheumatic drugs (cDMARDs) are the cornerstone of RA treatment and are fun-
damental to prevent radiologic progression on long-term [1]. Maximum treatment benefits
can, however, only be achieved if patients adhere to their treatment [6]. Previous research in
patients with RA revealed that adherence rates to DMARDs varied from 30% to 107%, depend-
ing on the used measurement method [7]. So far, interventions designed to improve medica-
tion adherence were only partly effective in changing medication-taking behaviour [8–10].
An explanation for the ineffectiveness of adherence-improving interventions might be that
previous studies have largely focused on patient’s explicit, ‘conscious’, evaluations of e.g. medi-
cation or medication-taking behaviour [11,12]. These interventions are often designed on the
basis of theories such as the theory of planned behaviour and the health belief model, which
form the backbone for understanding how explicit evaluations affect behaviour [11–14]. How-
ever, extensive theoretical and empirical contributions in the field of psychology demonstrate
that behaviour is only partly driven by conscious, explicit evaluations [11,15–20]. A lot of
behaviour originates from more subconscious or automatic processes (i.e. implicit associa-
tions) [11,15–20]. Dual process theories, which account for both reflective (conscious) as well
as automatic (subconscious) drivers of behaviour, are well-accepted in various scientific
domains aimed at unravelling the mechanisms underlying human behaviour (i.e., psychology,
behavioural economics, marketing, communication)[21,22]. Adherence research, in contrast,
has rarely tapped into this knowledge base, generally ignoring patients’ automatic associations
with their medication or medication-taking behaviour. The way to tap into these automatic
processes is to infer people’s associations from speeded response tasks (implicit measurement),
rather than ask them to introspect (explicit measurement)[23,24]. In this study, we used such
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implicit measurements with the aim to tap into automatically activated associations that are
based on a past experience and mediate favourable or unfavourable feelings that individuals
may not be aware of [16,18,21]. We refer to these associations as implicit attitudes, following
the evidence that implicit measurements are capable of exposing automatic positive or nega-
tive associations, but acknowledging that they do not by definition do so and that implicit
refers to the measurement rather than to the process per se [23,25,26]. Explicit attitudes, on
the contrary, are defined as deliberate or (sub)conscious evaluations of medication [16,18,21].
To date, few studies have investigated implicit attitudes towards medication and their
potential relation to medication-taking behaviour [27–29]. No strong correlation between
implicit and explicit attitudes towards medication was previously found, nor between implicit
attitudes and self-reported (thus explicitly measured) medication-taking behaviour [27,28].
This was no surprise, given that 1) implicit and explicit processes are known to deviate (cf.
dual process models and findings), and 2) self-report to assess medication-taking behaviour is
susceptible to the limits of patient’s self-knowledge and the tendency to provide socially desir-
able answers, and may therefore deviate from actual behaviour [21,30]. Assessing medication-
taking behaviour based on self-reports is therefore an important limitation in previous
research on implicit and explicit attitudes [27,28]. It can be argued that explicit determinants
assessed with self-report correlate more strongly with self-reported behaviour (because both
are assumed to be driven by elaborative thought), whereas implicit attitudes may have the
potential to correlate uniquely with actual behaviour, which is known to be driven largely by
automatic or subconscious processes [23,27]. Objective measurement methods, such as elec-
tronic drug monitors, are therefore more suitable to examine implicit attitudes’ relation with
actual medication-taking behaviour.
Therefore, the primary objective of this study is to explore the contribution of implicitly
measured attitudes towards cDMARDs, alongside explicit measures, on medication-taking
behaviour (i.e. measured subjectively with self-report and objectively with electronic drug
monitors) of patients with RA. The secondary objective is to explore the contribution of
implicitly measured attitudes towards cDMARDs, alongside explicit measures, on disease
activity scores in patients with RA.
Methods
Study design and setting
An observational study was conducted in two of the largest specialised rheumatology centres
across the Netherlands (i.e. covering approximately 20% of all patients with RA): Sint Maar-
tenskliniek (Nijmegen) and Reade (Amsterdam). Participants were recruited between July 5th,
2016 and November 30th, 2017. The STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) statement for observational studies and EMERGE (ESPACOMP
Medication Adherence Reporting Guideline) were used as guidance for adequate reporting of
this study (See S1 Table for all the abbreviations used in this study) [31,32].
Eligibility criteria and patient selection
Consecutive adult (� 18 years) patients with a clinical diagnosis of RA, treated with at least
one cDMARD for a minimum period of one year were invited to participate in this study. No
additional in- and exclusion criteria were defined. Four weeks before their planned regular
consultation with their treating clinician, patients received written information and an
informed consent form. After one to two weeks, patients were approached by telephone to ask
about their willingness to participate in this study. In case patients agreed to participate, the
Implicit and explicit attitudes towards disease-modifying antirheumatic drugs
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researcher planned a research appointment before their regular consultation in order to sign
the informed consent form and complete baseline measurements.
Study outcomes
Primary outcome of this study was medication-taking behaviour measured over a period of
three months after inclusion. Both self-report (i.e. the validated Compliance Questionnaire on
Rheumatology (CQR)) and electronic drug monitors (i.e. Medication wAardex1)) were used
to assess the implementation of the dosing regimen [33–35]. The operational definition for the
implementation of dosing regimens was correct dosing, which is defined as the proportion of
days with the correct number of doses taken [33,36]. Patients were considered to be adherent
if the proportion of correct days was >80% based on the prescribed medication regimen by
the health professional. Continuous adherence data were used for nested linear regression
models. Patient’s disease activity score (DAS28-CRP) was the secondary outcome measure,
which was assessed in conformity with treatment protocols as part of standard care [1,37].
Variables and data collection
Baseline measurements were performed in the consulting room of the outpatient pharmacy.
The following data were collected with a hardcopy questionnaire at baseline: socio-demo-
graphic characteristics (i.e. age, sex, educational level, living status, ethnicity), explicit attitudes
and health-related associations with cDMARDs with a bipolar evaluative adjective scale (8
items to evaluate positive-negative attitudes, 10 items to evaluate health-sickness related associ-
ations), beliefs about medicines with the Beliefs about Medicines Questionnaire Specific
(BMQ-Specific, 10 Likert-scaled items, ranging from 1 to 5), and self-reported medication-tak-
ing behaviour with the validated CQR with 19 Likert-scaled (ranging from 1 to 4) items
[33,34,38]. Implicit attitudes and health-related associations were collected with Single Cate-
gory Implicit Association Tests (SC-IATs), which were performed on a laptop in the consult-
ing room of the outpatient pharmacy [24,39,40]. Clinical characteristics (i.e. disease duration,
serology, type and current number of DMARD(s), disease activity scores) were extracted from
patient’s medical file by the local researchers. Patient diaries were handed at baseline in order
to let patients register possible unintended openings of MEMS. Follow-up measurements were
performed at the day of the next planned regular consultation, with a minimum and maximum
interval between baseline- and follow-up visits of three and nine months, respectively. At fol-
low-up visit, MEMS read-outs were used to assess correct dosing over the previous months.
Measurement instruments
Single category implicit association tests (SC-IATs). SC-IATs (Inquisit version 5) were
used to measure automatic associations [24,39–41]. The SC-IAT is considered a reliable and
valid instrument to measure implicit associations, which in this study is constituted of two
concepts, i.e. attitudes towards cDMARDs (positive versus negative) and health-related associ-
ations with cDMARDs (health versus sickness). The measurement of each concept included
three rounds: one practice round of 20 trials followed by two experimental rounds of 40 trials
each (see S1 File). Each trial was defined as a computerised categorisation task in which auto-
matic associations were measured based on patient’s response times. The response times in the
experimental rounds serve as a proxy for association strength, where faster responses represent
stronger associations. For instance, if patients were on average faster in trials coupling drug sti-
muli and positive (versus negative) stimuli, this reflects a relatively positive (versus negative)
automatic association with cDMARDs. S1 File provides a more detailed description of the
Implicit and explicit attitudes towards disease-modifying antirheumatic drugs
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SC-IATs procedures used in this study. The design and procedures of the SC-IATs were based
on the pilot study of Linn et al [27].
Explicit medication attitudes, health-related associations and beliefs about medicines.
Explicit attitudes (10 items, e.g. I think [name cDMARD] is 1 negative– 5 positive) and explicit
health-related associations (8 items, e.g. ‘to what extent do you associate [name cDMARD]
with the following terms’, 1 dead– 5 alive) were assessed with a bipolar evaluative adjective
scale. The items were identical to those in the SC-IATs (see S2 File for the complete list of
words used in the bipolar evaluative adjective scale). Medication necessity and concern beliefs
were assessed with the validated Beliefs about Medicines Questionnaire (BMQ) Specific (10
items, 5 necessity items and 5 concern items) [38]. Item scores varied from 1 (strongly dis-
agree) to 5 (strongly agree), which resulted in sum scale scores of 5 to 25 for each subscale
(necessity beliefs versus concern beliefs).
Study size
A common rule of thumb is to formulate sample size requirements as events per variable, with
a minimum of 10 events per variable. Assuming a sample size requirement of 10 non-adherent
patients per variable and a prevalence of 33% of non-adherence, a sample of 240 patients is suf-
ficient to build a reliable logistic model including a maximum of 8 independent variables. Tak-
ing into account 15% loss to follow-up, a sample size of 275 patients was required.
Statistical methods
Statistical analyses were performed with STATA version 13.1. Descriptive statistics were used
to describe patient characteristics by using mean (SD) or median (P25-P75) depending on the
distribution of measurements. Educational level was classified in low, moderate or high educa-
tional level. Low educational level was defined as no education, (extended) primary education
or pre-vocational education, moderate educational level was defined as vocational education
or selective secondary education, and high educational level was defined as education provided
by universities of applied sciences and research universities. Data were presented as percent-
ages in case of proportions. P-values�0.05 were considered statistically significant.
Implicit attitudes and health-related associations were assessed in terms of response times
in milliseconds (ms) on the SC-IATs. The improved IAT scoring algorithm described by
Greenwald et al. was used as scoring procedure to calculate the D measure for strength of auto-
matic associations [42]. S1 File provides a detailed description of the statistical methods to cal-
culate D measures. D measures above 0 indicated that patients had relatively faster response
times on positive categorisation rounds than on negative categorisation rounds, and were
interpreted as a relatively more positive than negative implicit attitude towards cDMARDs or
a relatively more health-related association than sickness-related association, and vice versa.
For explicit attitudes, mean sum scale scores were calculated for each concept (i.e. attitudes
and health-related associations). Patients with a mean scale score below or equal to 3 were con-
sidered to be relatively negative or have sickness-related associations with cDMARDs, whereas
patients with mean scale scores higher than 3 were considered to be relatively positive or asso-
ciated their cDMARD use with health. Beliefs about medicines were operationalised as neces-
sity-concerns differential (NCD) scores [38,43]. This NCD was calculated by subtracting the
sum of the item scores for concerns from the sum of item scores for necessity beliefs. A nega-
tive NCD indicated that concern beliefs predominate necessity beliefs and vice versa [38,43].
Participants were also categorised in attitudinal profiles based on their (in)congruent
(implicit and explicit) attitudes and health-related associations based on the cut-off scores for
implicit and explicit attitudes and health-related associations as described above. Depending
Implicit and explicit attitudes towards disease-modifying antirheumatic drugs
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on the distribution and type of variables, Two-sample t-tests, Pearson chi-square tests, Fisher’s
exact tests, Bonferroni corrected post-hoc tests, and proportion tests were performed to test
for significant differences in patient characteristics between study sites and attitudinal profiles.
Self-reported medication-taking behaviour was calculated with the discriminant function
for CQR items as described by de Klerk et al [33]. The critical cut-off score of -2.0046 for cor-
rect dosing�80% was used to identify adherent and non-adherent patients [33]. Medication-
taking behaviour measured with self-report was compared with medication-taking behaviour
measured with MEMS. The percentage of adherent patients per day was calculated over time
during three months follow-up and presented per attitudinal profile. The proportion of
patients in remission was presented for each attitudinal profile based on the cut-off scores for
DAS28-CRP and DAS28-BSE, as described by Fleischmann et al [37].
Spearman rank correlations were used to describe the correlation between patient’s implicit
and explicit outcomes, medication-taking behaviour (i.e. measured by self-report and using
MEMS), and clinical outcomes. Because of the explorative (rather than hypothesis-testing)
character of this study, no multiple testing corrections were performed over the separate corre-
lational analyses. Nested linear regression models (i.e. by sequentially adding blocks of vari-
ables) were used to assess the additional value of implicit measures, over explicit measures and
patient characteristics, in explaining adherence to medication and disease activity scores in
patients with RA. For each separate model three dependent continuous variables were used:
correct dosing based on (1) the CQR discriminant function, and (2) MEMS data, followed by
(3) DAS28-CRP scores at baseline.
Ethical approval
This study was conducted according to the ethical principles for medical research as stated in
the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013)
and was approved by the Medical Research Ethics Committee of Arnhem-Nijmegen (File:
2016–2410).
Patient and public involvement
Two patient research partners were involved in the design phase of this study. Those patient
research partners pretested the Single Category Implicit Association Tests and assessed the
comprehensibility of the hardcopy questionnaire for patients with rheumatoid arthritis.
Results
Study sample characteristics
Of the 1,659 initially invited patients, 254 patients agreed to participate in this study. The over-
all response rate was 15.3% (Nijmegen: 15.4%; Amsterdam: 15.0%). Fig 1 presents an overview
of patient recruitment, patient inclusion and drop-outs during follow-up. Participants had a
mean age of 62.8 (SD:11.2) years, 68.1% was female, 32.9% of the patients was highly educated,
and 22.2% was living alone. The mean disease duration of patients was 11.8 (SD:9.0) years and
biologic DMARDs were prescribed to 32.7% of the included patients. Methotrexate tablets
were significantly more often prescribed in Amsterdam compared to Nijmegen (resp. 77.5%
versus 40.4%, P<0.0001), whereas methotrexate subcutaneous injections were significantly
more often prescribed in Nijmegen than in Amsterdam (resp. 31.1% versus 7.0%, P = 0.0001).
Table 1 provides an overview of all patient characteristics. Due to different treatment protocols
applied at both study sites, DAS28-CRP scores were only available for patients treated in Nij-
megen (N = 152).
Implicit and explicit attitudes towards disease-modifying antirheumatic drugs
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Of the 254 patients who agreed to participate, 98.8% completed all SC-IATs, 98.0% the
bipolar evaluative adjective scale, 98.8% the BMQ-Specific, 99.2% the CQR and 91.7% of the
patients provided MEMS data. The main reason for missing MEMS data was discontinuation
of cDMARD therapy (Fig 1). Continuous CQR adherence data instead of dichotomous data
were used in this study, since the validation of the CQR against MEMS together with the arbi-
trary cut-off score of 80% has been subject to considerable debate [44,45]. The proportion of
correct trials in the SC-IAT experimental rounds for the positive-negative concept was 93.3%
and for the health-sickness concept 95.5%. No participants were excluded for further data-
analysis of implicit data.
Patient’s implicit and explicit attitudes and associations, including beliefs
about medication
The mean D measure for implicit attitudes towards cDMARDs was -0.054 (SD: 0.42, range:
-1.26; 1.21, skewness: -0.11, kurtosis: 2.81), whereas the mean D measure for implicit health-
related associations with cDMARDs was -0.10 (SD: 0.38, range: -1.25; 1.03, skewness: -0.03,
kurtosis: 3.24). The mean score for explicit attitudes of patients who completed the bipolar
evaluative adjective scale was 3.5 (SD:0.72, range: 1.4; 5, skewness: -0.24, kurtosis: 3.25), which
was similar for explicit health-sickness associations with cDMARDs (M = 3.6, SD: 0.89, range:
1; 5, skewness: -0.26, kurtosis: 2.47). Regarding beliefs about medicines, the mean sum scale
score for necessity beliefs and for concern beliefs was 19.9 (SD: 3.6, range: 5; 25, skewness:
-0.78, kurtosis: 3.9) and 14.1 (SD: 3.9, range: 5; 25, skewness: -0.18, kurtosis: 2.58), respectively.
The mean necessity-concerns differential score of 5.8 (SD: 5.2, range: -16; 19, skewness: -0.17,
kurtosis: 3.8) indicates that necessity beliefs outweigh patient’s concerns about medication.
Patient’s implicit attitudes (D measure) and explicit attitudes (mean score measured with
the bipolar evaluative adjective scale) were not significantly correlated (ρ = 0.09, P = 0.16),
however a significant weak correlation was found between mean D measures for implicit atti-
tudes and necessity-concerns differential scores (ρ = 0.13, P = 0.05, illustrated in Fig 2). Also
implicit health-related associations were significantly (yet weakly) correlated with mean scores
for explicitly reported health-related associations (ρ = 0.18, P = 0.004). No significant
Fig 1. Flowchart of study participants.
https://doi.org/10.1371/journal.pone.0221290.g001
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correlation was found between implicit health-related associations and NCD-scores (ρ = 0.09,
P = 0.18).
Implicit attitudes (D measure) were not correlated with self-reported correct dosing (ρ =
-0.03, P = 0.68), nor with MEMS correct dosing (ρ = 0.06, P = 0.40). However, a weak signifi-
cant negative correlation between D measures for implicit attitudes and disease activity scores
was found (ρ = -0.17, P = 0.04), where more negative implicit attitudes (D measures) were
associated with higher disease activity scores. No correlations were found between implicit
health-related associations and any of the following variables: correct dosing measured with
self-report (ρ = 0.04, P = 0.51), correct dosing measured with MEMS (ρ = -0.002, P = 0.97),
and disease activity scores (ρ = -0.07, P = 0.42).
Explicit attitudes (measured with a bipolar evaluative adjective scale) were not correlated
with self-reported correct dosing (ρ = 0.10, P = 0.12), MEMS correct dosing (ρ = 0.10,
P = 0.13), and disease activity scores (ρ = -0.09, P = 0.30). Also explicit health-related associa-
tions were not correlated with MEMS correct dosing (ρ = 0.11, P = 0.08), however, a significant
negative correlation was found between explicit health-related associations and disease-activity
Table 1. Study sample characteristics.
Study sample characteristics at baseline Amsterdam
(N = 71)
Nijmegen
(N = 183)
Overall
(N = 254)
P-value
Patient characteristics
Age in years, mean (SD) 63.4 (11.2) 62.5 (11.2) 62.8 (11.2) 0.60
Female, N (%) 49 (69.0) 124 (67.8) 173 (68.1) 0.85
High educational level, N (%) 26 (36.6) 57 (31.1) 83 (32.7) 0.44
Living alone, N (%) 27 (38.0) 29 (15.8) 56 (22.0) <0.001
Dutch ethnic background, N (%) 68 (95.8) 176 (96.2) 244 (96.1) 0.55
Disease characteristics
Disease duration in years, mean (SD) 10.9 (8.8) 12.1 (9.1) 11.8 (9.0) 0.34
Rheum factor positive serology, N (%) 48 (67.6) 123 (67.2) 171 (67.3) 0.85
Anti-CCP positive serology, N (%) 50 (70.4) 116 (63.4) 166 (65.4) 0.44
Number of comorbidities, mean (SD) 2.0 (1.7) 2.2 (1.8) 2.1 (1.8) 0.45
Proportion of RA patients in remission, N (%) 11 (15.5) 95 (51.9) 106 (41.7) 0.04
Treatment characteristics
Number of DMARDs, mean (SD) 1.5 (0.7) 1.6 (0.5) 1.6 (0.6) 0.62
Corticosteroids, N (%) 32 (45.1) 31 (16.9) 63 (24.8) <0.001
Methotrexate oral, N (%) 55 (77.5) 74 (40.4) 129 (50.8) <0.001
Methotrexate subcutaneous, N (%) 5 (7.0) 57 (31.1) 62 (24.4) <0.001
Leflunomide, N (%) 2 (2.8) 22 (12.0) 24 (9.4) 0.02
Sulfasalazine, N (%) 10 (14.1) 11 (6.0) 21 (8.3) 0.04
Azathioprine, N (%) 0 (0.0) 12 (6.6) 12 (4.7) 0.03
Hydroxychloroquine, N (%) 23 (32.4) 40 (21.9) 63 (24.8) 0.08
Biologic DMARDs, N (%) 13 (18.3) 70 (38.2) 83 (32.7) <0.01
Other drugs than DMARDs, mean (SD) 4.8 (3.5) 6.9 (4.6) 6.3 (4.4) <0.0001
Self-reported medication-taking behaviour
CQR correct dosing, adherent, N (%) 62 (87.3) 170 (92.9) 232 (91.3) 0.08
Categories were high versus medium-low for educational level, living alone versus living together (with children and/or partner) for residential status, and for ethnic
background Dutch versus other. High educational level included a university degree or a degree in universities of applied sciences. P-values were calculated by Pearson
chi-square tests or Two-sample t-tests. P-values�0.05 were considered statistically significant. Abbreviations: CQR (Compliance Questionnaire on Rheumatology);
DMARDs (disease-modifying antirheumatic drugs); RA (rheumatoid arthritis).
https://doi.org/10.1371/journal.pone.0221290.t001
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scores (ρ = -0.21, P = 0.01), and a significant positive correlation with self-reported correct
dosing (ρ = 0.13, P = 0.05). NCD-scores were significantly correlated with self-reported correct
dosing (ρ = 0.26, P<0.0001), but not with MEMS correct dosing and disease activity scores.
Congruent and incongruent (implicit and explicit) attitudinal profiles
Fewer patients displayed implicit positive attitudes (47.2%) and health-related associations
(39.6%) regarding cDMARD therapy than when explicitly asked (75.6% and 67.3%, respec-
tively). Based on D measures for implicit attitudes and mean scores for explicit attitudes from
the bipolar evaluative adjective scale, patients were categorized in four attitudinal profiles per
concept, indicating the (in)congruently positive or negative nature of their implicit and explicit
attitudes (see Table 2 for an overview of subgroup characteristics for each attitudinal profile
for the concept positive-negative). About half of all participants displayed incongruent
(implicit and explicit) attitudes and health-related associations (46.3% and 49.0%,
respectively).
Bonferroni corrected post-hoc tests revealed that congruently negative patients (profile III)
differed significantly in age, NCD-scores, bDMARD use and self-reported correct dosing from
other attitudinal profiles. Congruently negative patients were on average 6.1 years younger
(95%CI: -11.74; -0.46, P = 0.03) than congruently positive patients, reported more concerns
than explicitly positive patients (contrast with profile I: -4.92, 95%CI: -7.42; -2.41, P<0.001;
contrast with profile II: -4.92, 95%CI: -7.46; -2.43, P<0.001), more often used bDMARDs than
all other attitudinal profiles (contrast with profile I: 26.5%, P = 0.004; contrast with profile II:
23.7%, P = 0.01; contrast with profile IV: 41.6%, P = 0.001) and were less often adherent based
on self-reported correct dosing than the other attitudinal profiles (contrast with profile I:
13.6%, P = 0.03; contrast with profile II: 15.6%, P = 0.007; contrast with profile IV: 21.1%,
P = 0.02). When exploring the proportion of adherent patients measured with MEMS over
Fig 2. Correlation between implicit attitudes (D measure) and explicit beliefs about medication (necessity-
concerns differential scores). Higher NCD-scores indicate that necessity beliefs outweigh concern beliefs, whereas
higher D measures for implicit attitudes indicate more positive attitudes towards cDMARDs (ρ = 0.13, P = 0.05).
Abbreviations: cDMARD (conventional disease-modifying antirheumatic drug), NCD (necessity-concerns
differential).
https://doi.org/10.1371/journal.pone.0221290.g002
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time between different profiles, similar patterns emerge within the four attitudinal profiles
(Fig 3). However, the proportion of adherent patients with negative explicit attitudes (profiles
Table 2. Description of profiles of patients diagnosed with rheumatoid arthritis based on (in)congruent implicit and explicit attitudes.
Profile I Profile II Profile III Profile IV P-value
Attitudes towards cDMARDs Explicit Positive Positive Negative Negative
Implicit Positive
(N = 94)
Negative (N = 92) Negative (N = 38) Positive (N = 22)
Patient characteristics
Age in years, mean (SD) 63.8 (10.7) 63.2 (11.4) 57.7 (12.5) 62.5 (7.7) 0.05
Female, N (%) 62 (66.0) 60 (65.2) 29 (76.3) 15 (68.2) 0.64
High educational level, N (%) 39 (41.5) 23 (25.0) 11 (28.9) 9 (40.9) 0.09
Living alone, N (%) 22 (23.4) 20 (21.7) 10 (26.3) 2 (9.1) 0.45
Clinical characteristics
Disease duration in years, mean (SD) 10.9 (9.0) 12.2 (8.1) 10.3 (9.0) 15.9 (12.3) 0.10
Anti-CCP positive, N (%) 58 (61.7) 64 (69.6) 23 (60.5) 16 (72.7) 0.49
Number of comorbidities, mean (SD) 2.3 (1.9) 2.3 (1.8) 1.5 (1.6) 2.0 (1.4) 0.04
Treatment characteristics
Number of DMARDs, mean (SD) 1.6 (0.6) 1.5 (0.6) 1.7 (0.6) 1.4 (0.7) 0.03
Using bDMARDs, N (%) 27 (28.7) 29 (31.5) 21 (55.3) 3 (13.6) 0.005
Beliefs about medicines
Necessity-concerns differential, mean (SD) 6.7 (4.3) 6.7 (5.1) 1.7 (5.6) 4.7 (4.6) 0.0001
Study outcomes
Correct dosing: proportion of adherent patients based
on self-report, N (%)
87 (92.6) 87 (94.6) 30 (78.9) 22 (100) 0.01
Correct dosing, proportion of adherent patients based
on MEMS, N (%)
77 (84.6) 76 (90.5) 25 (75.8) 16 (76.2) 0.15
DAS28-CRP, mean (SD) 2.15 (1.0) 2.13 (0.9) 2.6 (1.2) 2.4 (1.5) 0.34
Proportion of patients in remission, N (%) 40 (42.6) 41 (44.6) 13 (34.2) 8 (36.4) 0.47
Categories were low versus medium-high for educational level, living alone versus living together (with children and/or partner) for residential status, and for ethnic
background Dutch versus other. Variables with unadjusted P-values�0.05 were considered statistically significant and were further analysed with Bonferroni corrected
post-hoc tests. Abbreviations: DMARDs (disease-modifying antirheumatic drugs), bDMARD (biologic DMARD), MEMS (Medication Event Monitoring System),
DAS28-CRP (Disease Activity Score based on 28 joints and C-Reactive Protein).
https://doi.org/10.1371/journal.pone.0221290.t002
Fig 3. The proportion of adherent patients with rheumatoid arthritis over time based on MEMS correct dosing
adherence. Based on D measures and mean scale scores for explicit attitudes, patients were categorized in (in)
congruent positive or negative attitudinal profiles.
https://doi.org/10.1371/journal.pone.0221290.g003
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III and IV) more often dropped below the 80% level than for the positive explicit attitudinal
profiles (I and II). The small number of patients categorised in these explicitly negative profiles
might have contributed to these findings. Additionally, the largest difference in proportion of
adherent patients between both measurement instruments (self-report versus MEMS) was
found for patients assigned to profile IV. No significant differences between attitudinal profiles
were found in the number of comorbidities and the total number of DMARDs after Bonfer-
roni adjusted post-hoc tests.
Subgroup characteristics for each profile regarding health-related associations can be found
in S2 Table. Patients who displayed congruently sickness-related associations with cDMARDs
differed significantly in NCD-scores from patients who reported explicit (regardless of their
implicit) health-related associations (contrast with profile I: -4.1, P<0.001; contrast with pro-
file II: -3.0, P = 0.002). In other words, patients who displayed congruent (implicit and explicit)
sickness-related associations with cDMARDs had more concerns about their medication than
patients who reported explicit health-related associations with cDMARDs. The same applied
for patients categorised in profile IV compared with patients categorised in profile I (contrast:
-6.2, P<0.001) and profile II (contrast:-5.0, P<0.001). The mean number of DMARDs in the
congruently sickness-related subgroup was significantly higher than the mean number of
DMARDs in the congruently health-related subgroup (contrast: 0.29, P = 0.04). When explor-
ing the proportion of adherent patients measured with MEMS over time between the different
health-related attitudinal profiles, results were similar to those of the positive-negative concept
(data not shown).
Added value of implicit attitudes in explaining medication-taking
behaviour and clinical outcomes
The skewed MEMS data (i.e. high proportion of adherent patients), even after data transfor-
mation, did not meet the assumptions for linear regression modelling. Medication-taking
behaviour measured with MEMS was, therefore, excluded for nested linear regression model-
ling. Nested linear regression models showed that only age and NCD-scores contributed sig-
nificantly when the dependent variable was correct dosing measured with self-report.
However, no variables measured in this study contributed significantly to disease activity
scores. Implicit attitudes and implicit health-related associations, alongside patient characteris-
tics and explicit measures, had no added value in explaining variance in medication-taking
behaviour when measured with self-report. The same applied for disease activity scores (see
Table 3 and Table 4). Overall, determinants measured in this study explained approximately
11 to 17% of the variance in medication-taking behaviour and disease activity scores.
Discussion
This study showed that implicit attitudes and health-related associations do not explain medi-
cation-taking behaviour and clinical outcomes in clinical practice over and above 1) patient
characteristics, 2) clinical variables, 3) treatment characteristics, 4) explicit attitudes and
health-related associations, or 5) beliefs about medicines. Only age and NCD-scores contrib-
uted significantly to medication taking behaviour measured with self-report. However, some
significant but weak associations were found between implicit attitudes and necessity-concerns
differential scores, between implicit and explicit health-related associations, and implicit atti-
tudes and disease activity. The categorization of patients in combined implicit and explicit atti-
tudinal profiles revealed that characteristics of in particular patients with congruently negative
or congruently sickness-related associations, differed from other attitudinal profiles.
Implicit and explicit attitudes towards disease-modifying antirheumatic drugs
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Table 3. Results nested linear regression models: Contribution of implicit attitudes over and above patient characteristics, disease characteristics, treatment charac-
teristics and explicit measures in patients with rheumatoid arthritis.
Correct dosing: self-report DAS28-CRP
Coefficient R2 Coefficient R2
(95%CI) (ΔR2) (95%CI) (ΔR2)
Block 1: Patient characteristics
Age (years) 0.02� -0.01
(0.003; 0.04) (-0.03; 0.01)
Female (y/n) -0.40 0.27
(-0.82; 0.02) (-0.13; 0.67)
High educational level 0.20 -0.20
(-0.21; 0.60) (-0.60; 0.20)
Living alone (y/n) -0.11 0.17
(-0.61; 0.39) (-0.35; 0.69)
Hospital Nijmegen (y/n) 0.07 NA
(-0.39; 0.52)
0.064 0.044
Block 2: Disease characteristics
Disease duration (years) -0.01 -0.002
(-0.03; 0.01) (-0.023; 0.02)
Anti-CCP positive (y/n) -0.06 0.03
(-0.50; 0.37) (-0.38; 0.45)
Number of comorbidities 0.02 -0.03
(-0.11; 0.16) (-0.16; 0.09)
0.076 0.046
(0.012) (0.002)
Block 3: Treatment characteristics
Number of DMARDs 0.06 -0.07
(-0.34; 0.47) (-0.57; 0.44)
bDMARD use (y/n) 0.10 0.15
(-0.44; 0.64) (-0.42; 0.71)
N of other drugs than DMARDs 0.04 0.05
(-0.02; 0.10) (-0.002; 0.096)
0.098 0.075
(0.022) (0.028)
Block 4: Beliefs about medicines
Necessity-concerns differential score 0.08�� -0.02
(0.04; 0.13) (-0.06; 0.02)
0.163 0.097
(0.065) (0.023)
Block 5: Explicit attitudes (bipolar evaluative adjective scale): positive versus negative
Mean score for explicit attitudes -0.09 -0.16
(-0.40; 0.22) (-0.46; 0.13)
0.165 0.107
(0.002) (0.009)
Block 6: Implicit attitudes (concept: positive versus negative)
D measure 0.01 -0.007
(-0.45; 0.48) (-0.43; 0.41)
(Continued)
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To our knowledge, this is the first study which compares groups of patients with congruent
and incongruent implicit and explicit attitudes towards medication in relation to objectively
measured medication-taking behaviour and clinical outcomes in patients with RA. Linn et al
already emphasized the importance of exploring implicit associations as possible targets for
improving actual (rather than self-reported) medication adherence in this population [27]. In
terms of (in)congruent implicit and explicit attitudes towards medication, our findings are in
line with the findings reported by Linn et al and Ru¨sch et al, which supports the idea that
implicit and explicit measures are different but related constructs [27,28]. However, contrary
to our expectations, patient’s implicit associations did not significantly explain variance in
objectively measured medication-taking behaviour. Several possible explanations can be given
to elucidate this finding.
One explanation is that no association between implicit associations and objectively mea-
sured medication-taking behaviour in clinical practice exist. In other words, implicit associa-
tions (with cDMARDs) do not underlie (medication-taking) behaviour. This finding is
contrary to previous studies [11,21,46,47]. However, the concept of predicting behaviour by
implicit measures was recently challenged by studies demonstrating that correlations between
implicit measures and measures of behaviour are often small to medium[48–50]. Person-, con-
text-, and behaviour-specific moderators might be responsible for these contradictory findings
[25,48,49]. For instance, medication-taking behaviour can be seen as a more habitual, recur-
rent behaviour that might initially originate in conscious thought processes (“I should not for-
get my medication”), whereas some of the other examined behaviours can be argued to be less
habitual and frequent (e.g., voting) and less rooted in conscious thought (e.g., brand prefer-
ences). The second explanation for the current findings might be that implicit processes do
underlie objectively measured medication-taking behaviour, but were not detected in our
study due to methodological limitations, described below.
Methodological considerations
The key strengths of this study are the large sample size and patient recruitment in two of the
largest rheumatology specialized centres across the Netherlands (i.e. covering approximately
20% of all patients with RA). Another strength is the use of MEMS to objectively measure
medication-taking behaviour over three months in addition to the assessment of medication-
taking behaviour by self-report. Measuring medication-taking behaviour by self-report is
more susceptible to recall bias [30]. In contrast with Ru¨sch et al, we used validated question-
naires to assess self-reported adherence and beliefs about medicines [28]. An advantage of
using both (validated) questionnaires and MEMS is the ability to compare both measurement
instruments. However, MEMS is considered as gold standard method, since this method
Table 3. (Continued)
Correct dosing: self-report DAS28-CRP
Coefficient R2 Coefficient R2
(95%CI) (ΔR2) (95%CI) (ΔR2)
Total R2 0.165 0.107
(0.000) (0.000)
Level of significance
� P-value<0.05
��P-value<0.001
NA: Not applicable
https://doi.org/10.1371/journal.pone.0221290.t003
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Table 4. Results nested linear regression models: contribution of implicit health-related associations over and above patient characteristics, disease characteristics,
treatment characteristics and explicit measures in patients with rheumatoid arthritis.
Correct dosing: self-report DAS28-CRP
Coefficient R2 Coefficient R2
(95%CI) (ΔR2) (95%CI) (ΔR2)
Block 1: Patient characteristics
Age (years) 0.02� -0.009
(0.003; 0.04) (-0.03; 0.011)
Female (y/n) -0.40 0.25
(-0.82; 0.02) (-0.15; 0.64)
High educational level 0.20 -0.20
(-0.20; 0.61) (-0.59; 0.19)
Living alone (y/n) -0.11 0.15
(-0.62; 0.39) (-0.37; 0.67)
Hospital Nijmegen (y/n) 0.06 NA
(-0.39; 0.51)
0.064 0.044
Block 2: Disease characteristics
Disease duration (years) -0.01 -0.001
(-0.03; 0.01) (-0.22; 0.02)
Anti-CCP positive (y/n) -0.06 0.06
(-0.49; 0.37) (-0.36; 0.47)
Number of comorbidities 0.02 -0.04
(-0.12; 0.16) (-0.17; 0.08)
0.076 0.046
(0.012) (0.002)
Block 3: Treatment characteristics
Number of DMARDs 0.06 -0.10
(-0.35; 0.47) (-0.61; 0.41)
bDMARD use (y/n) 0.11 0.14
(-0.43; 0.64) (-0.43; 0.70)
N of other drugs than DMARDs 0.04 0.05
(-0.02; 0.10) (-0.003; 0.09)
0.098 0.075
(0.022) (0.029)
Block 4: Beliefs about medicines
Necessity-concerns differential score 0.08�� -0.02
(0.04; 0.12) (-0.05; 0.02)
0.163 0.098
(0.065) (0.023)
Block 5: Explicit associations (bipolar evaluative adjective scale): health versus sickness
Mean score for explicit associations -0.03 -0.19
(-0.27; 0.22) (-0.42; 0.03)
0.164 0.119
(0.001) (0.021)
Block 6: Implicit associations (concept: health versus sickness)
D measure -0.005 -0.03
(-0.53; 0.52) (-0.54; 0.48)
(Continued)
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provides insight in more objectively measured daily medication-taking behaviour over time
compared with self-report at one time point [51]. Still, it is an assumption that MEMS device
usage corresponds with actual medication intake since intentional non-adherence to medica-
tion (e.g. opening MEMS without taking the medication) cannot be prevented in the home set-
ting of patients. The awareness of being monitored (i.e. Hawthorne effect), might have
contributed to the large proportion of adherent patients (i.e. the small amount of variation in
adherence measures, in particular when MEMS are used) that we have found in our study
when medication-taking behaviour was measured with both self-report and electronic drug
monitors. This small amount of variation might have limited the power of this study to detect
differences between adherent and non-adherent patients across attitudinal profiles, since high
adherence rates could indicate more conscious and rational (e.g. planned) intake behaviour or
high patient engagement with their treatment, in which case explicit attitudes and beliefs
about medicines would override (potentially different) implicit associations. As a consequence,
this might also limit the generalizability of the results.
The validity of the SC-IATs used in this study might be questioned since the target popula-
tion might have a limited hand function, which might provide insufficient contrast between
the experimental rounds in the SC-IATs. Also, it is unclear if the words and pictures used as
stimuli in the SC-IATs are optimally related to patient’s medication use [49]. However, pic-
tures were created based on pharmacy records in participating centres (i.e. manufacturer of
the drugs, type of packaging, and appearance of the drug) and SC-IATs were personalised
based on patient’s cDMARD use to increase the ability of patients to recognise their cDMARD
at a glance. Another methodological consideration was the cut-off score for categorizing
patients in attitudinal profiles based on (scale) midpoints for positive-negative attitudes and
health-sickness related associations. The large proportion of patients who displayed relatively
neutral implicit attitudes and associations (i.e. D measure near midpoint 0) or neutral explicit
attitudes or health-related associations (i.e. mean score near midpoint 3) might have reduced
the contrast in characteristics (e.g. patient-, clinical-,and treatment-related variables, beliefs
about medicines, medication-taking behaviour, and clinical outcomes) across attitudinal pro-
files. Currently, there is discussion in the literature on whether implicit measures by definition
expose automatic associations or subconscious attitudes or whether they might also be sensi-
tive to more reflective and conscious thought [25,26,48]. There is no consensus yet on the ter-
minology and nature of these implicit and explicit processes and measurements, on how these
constructs interact with each other, and how stable these constructs are over time and across
situations [23,25,26,48]. Future research should take these considerations into account.
Table 4. (Continued)
Correct dosing: self-report DAS28-CRP
Coefficient R2 Coefficient R2
(95%CI) (ΔR2) (95%CI) (ΔR2)
Total R2 0.164 0.119
(0.000) (0.000)
Level of significance
� P-value<0.05
��P-value<0.001
NA: Not applicable
https://doi.org/10.1371/journal.pone.0221290.t004
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Generalizability of the results
The external validity of the results might be questionable due to the low response rate of
patients, together with the high proportion of adherent participants. The latter might indicate
selection bias since it is well known that in adherence research often only highly motivated
patients are willing to participate in studies [52]. It is conceivable that our findings on MEMS
adherence are, therefore, an overrepresentation of adherence rates in the general RA popula-
tion. Also the large proportion of patients who had a Dutch ethnic background in a study site
which is located in a multicultural setting, together with the long disease duration, support the
idea of selection bias. Since we did not measure health literacy in this study, it is unknown if
patients with low health literacy skills were underrepresented in our study sample. However,
when comparing study participants to the general RA population in the Sint Maartenskliniek
(chosen as reference due to limited access of data of non-participating patients across study
sites), no significant differences were found in mean age, sex, and mean disease duration. The
proportion of study participants using a biologic DMARD was smaller than the proportion of
bDMARD users in the general population in the Sint Maartenskliniek (32.7% and 41.5%
respectively), whereas the proportion of patients who are in remission was higher in the gen-
eral RA population in the Sint Maartenskliniek compared to our study sample (71.5% and
41.7% respectively). The latter might also explain the large proportion of adherent patients,
since patients with high disease activity scores might be more motivated to participate in this
study and might also be more likely to adhere to their treatment during the study. It is also
assumed that our findings on patient’s implicit and explicit attitudes towards cDMARDs can-
not simply be extrapolated to biologic DMARDs and the recently introduced JAK-inhibitors.
Taking together, our study population might not be optimally representative for the entire RA
population, especially for patients with early RA, and ethnic minorities.
In conclusion, about half of the patients with RA showed incongruent (implicit and
explicit) attitudes and health-related associations with cDMARDs. Implicit attitudes and asso-
ciations had no additional value in explaining medication-taking behaviour and clinical out-
comes over and above often used explicitly measured characteristics, attitudes and outcomes
in the studied population. However, this research provides interesting areas for future research
regarding implicit and explicit processes that might be involved in medication-taking
behaviour.
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